Observational studyBMC geriatrics2024
Polypharmacy and drug interactions in older patients with cancer receiving chemotherapy: associated factors.
Observational study in BMC geriatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and determinants of polypharmacy among cancer patients: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Falls in older patients treated for cancer in French outpatient departments: screening and prevention-a prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Prevalence, associated factors, and prognostic impact of delirium in advanced cancer patients in acute palliative care units: a prospective observational study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Potentially Clinically Relevant Drug-Drug Interactions in Oncology Patients Receiving Chronic Opioid Therapy: Prevalence and Associated Factors.Life (Basel, Switzerland) · 2026Article
- Polypharmacy in Older Adults: A Narrative Review of Clinical Risks, Deprescribing Strategies, and Interdisciplinary Management.Geriatrics (Basel, Switzerland) · 2026Review
- Polypharmacy in Adults With Systemic Lupus Erythematosus.Arthritis care & research · 2026Article
- Iodinated Contrast Media in Oncologic CT: A Narrative Review of Safety, Risk Stratification, and Practical Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors.International journal of molecular sciences · 2026Review
- Tablet Acceptability in Older Outpatients Undergoing Cancer Chemotherapy.Geriatrics (Basel, Switzerland) · 2026Article
- Age-Associated Genetic Variations in Breast Cancer: Somatic Mutations and Co-Mutations.Biomedicines · 2026Article
- [Drug interactions in uro-oncology].Urologie (Heidelberg, Germany) · 2026Review
- Family Function and Medication Safety Behaviors in Older Adults with Cancer: A Serial Mediation Analysis.Patient preference and adherence · 2026Article
- Impact of CNS medication burden and drug interactions on delirium in patients with advanced cancer: a multicenter prospective observational study.Scientific reports · 2025Observational
- Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Advancing drug-drug interactions research: integrating AI-powered prediction, vulnerable populations, and regulatory insights.Frontiers in pharmacology · 2025Review
- Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model.Pharmaceutics · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy in older adults with cancer receiving chemotherapy leads to increased risks of drug interactions, translating in potential hazardous health outcomes. This study aims to assess the prevalence of polypharmacy, drug-drug interactions (DDIs), and severe-drug interactions (SDIs) in older patients with cancer. Antineoplastic agents (ANAs) involvement and possible risk contexts (comorbidities with cardiac risk, and high-risk medications) were also analysed.
methodsObservational study with older adults (≥ 65 years) diagnosed with cancer, who were treated with antineoplastic agents (ANAs); it was conducted in three hospitals from the north of Portugal. Data collection was obtained using self-reports and medical records. DDIs were identified and classified using Micromedex® software. Descriptive and association analyze statistics were performed. Statistical hypothesis tests with p value less than 0.05 were considered significant. All statistical procedures and analysis were performed with R version 4.1.3.
resultsWe enrolled 552 patients. Polypharmacy prevalence was 88.40%; 76.45% and 56.16% of the patients presented with DDIs and SDIs, respectively. SDIs with ANAs were found in 21.20% of the patients. High-risk medications were associated with a higher risk of polypharmacy, DDIs, and SDIs. Polypharmacy and DDIs were higher in patients with hypertension or diabetes. SDIs were higher in patients with diabetes.
conclusionPolypharmacy, potential DDIs and SDIs were highly prevalent in older adults with cancer. A careful review of the medication administered is necessary to decrease it. These findings warrant further research to optimize medication in this population and decrease problems related to medication, which may lead to emergency room visits and hospitalisations, compromising patient safety and/or ongoing treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.